Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy

BACKGROUND: T-cell-engaging CD3-bispecific antibodies (CD3-bsAbs) are promising modalities for cancer immunotherapy. Although this therapy has reached clinical practice for hematological malignancies, the absence of sufficient infiltrating T cells is a major barrier for efficacy in solid tumors. In...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Groeneveldt, Christianne, Kinderman, Priscilla, van den Wollenberg, Diana J M, van den Oever, Ruben L, Middelburg, Jim, Mustafa, Dana A M, Hoeben, Rob C, van der Burg, Sjoerd H, van Hall, Thorbald, van Montfoort, Nadine
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2020
Assuntos:
Oncolytic and Local Immunotherapy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7577070/
https://ncbi.nlm.nih.gov/pubmed/33082167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001191
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares